ED Medications Not Working? Here's What to Try Next

When Oral Medications Fail: A Comprehensive Guide to Advanced ED Treatment

PDE5 inhibitors — sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) — are the most widely prescribed first-line treatment for erectile dysfunction worldwide. They are effective, well-tolerated, and have transformed ED treatment since sildenafil's FDA approval in 1998.

However, approximately 30–35% of men do not respond adequately to PDE5 inhibitors (Carson et al., 2004, BJU International). For these men, the experience is doubly frustrating: they took the difficult step of seeking help, only to discover that the most commonly prescribed treatment doesn't work for them.

If this describes your experience, the most important message is this: PDE5 inhibitor failure does not mean treatment failure. There are multiple proven alternatives with success rates that exceed those of oral medications — and at ReGenesis, we offer all of them.

> "When a man tells me Viagra didn't work, my first question isn't 'What do we try next?' — it's 'Did we try Viagra correctly?' In my experience, a significant percentage of so-called PDE5 inhibitor failures are actually optimization failures. Before we escalate, we optimize." > — Dr. Lloyd Tapper, PhD, NP — Founder, ReGenesis

Why PDE5 Inhibitors Fail: The Seven Most Common Reasons

Before advancing to second-line therapies, it is essential to evaluate whether oral medication was given a fair trial. Research by McCullough et al. (2002, Journal of Urology) identified several common reasons for apparent PDE5 inhibitor failure:

1. Incorrect Administration

Problem: Taking sildenafil with a high-fat meal can delay absorption by 60+ minutes and reduce peak plasma concentration by 29% (Nichols et al., 2002, British Journal of Clinical Pharmacology).

Solution: Take sildenafil on an empty stomach or with a light, low-fat meal. Tadalafil is not affected by food and may be a better option for men who prefer to take medication with meals.

2. Insufficient Dosing

Problem: Many men are initially prescribed a moderate dose (e.g., sildenafil 50mg) and never titrate upward, even when response is suboptimal.

Solution: Clinical guidelines recommend trialing the maximum dose (sildenafil 100mg, tadalafil 20mg, vardenafil 20mg) before declaring treatment failure. A study by Hatzimouratidis et al. (2010) found that dose optimization converted approximately 30% of initial non-responders to responders.

3. Insufficient Trials

Problem: Some men try a medication once or twice and abandon it when it doesn't work immediately.

Solution: PDE5 inhibitors should be tried at least 6–8 times at optimal dose before being considered ineffective. Response often improves with repeated use as psychological anxiety diminishes.

4. Inadequate Sexual Stimulation

Problem: PDE5 inhibitors require sexual arousal to work — they enhance the natural erectile response but do not create it independently.

Solution: Ensure adequate foreplay and psychological engagement. Address relationship dynamics and communication.

5. Not Trying All Three Medications

Problem: Response varies between PDE5 inhibitors. A man who fails sildenafil may respond to tadalafil, and vice versa.

Solution: Trial all three available PDE5 inhibitors before concluding that the class is ineffective.

6. Untreated Underlying Conditions

Problem: Undiagnosed low testosterone, uncontrolled diabetes, untreated sleep apnea, or psychological conditions can undermine PDE5 inhibitor efficacy.

Solution: Comprehensive evaluation and treatment of comorbidities. A study by Shabsigh et al. (2004, Journal of Urology) found that adding testosterone therapy converted 60% of hypogonadal PDE5 inhibitor non-responders to responders.

7. Psychological Factors

Problem: Performance anxiety can override the pharmacological effect of PDE5 inhibitors. The medication improves blood flow, but the sympathetic nervous system activation from anxiety constricts it.

Solution: CBT, couples therapy, or short-term anxiolytic support in combination with PDE5 inhibitors.

> "Optimization before escalation — that's the principle. I've converted countless 'Viagra failures' into 'Viagra successes' simply by adjusting timing, dose, or addressing an untreated comorbidity. Only when true optimization fails do we move to advanced therapies." > — Dr. Lloyd Tapper, PhD, NP

Second-Line Therapies: When Optimization Isn't Enough

For men who have genuinely failed optimized PDE5 inhibitor therapy, several highly effective alternatives are available at our Edmonton and Calgary clinics:

Injectable Therapies: Trimix, Bimix, and Quadmix

Mechanism: Direct injection of vasoactive agents into the corpus cavernosum bypasses the NO-cGMP-PDE5 pathway entirely. The medications act directly on smooth muscle to produce vasodilation and erection — making them effective regardless of the mechanism causing PDE5 inhibitor failure.

Efficacy: Success rates exceed 85% (Coombs et al., 2012, BJU International), making injectable therapy the most reliable non-surgical ED treatment available.

Regenerative Therapies

P-Shot (PRP Therapy): Autologous platelet-rich plasma injected into the corpus cavernosum stimulates angiogenesis and tissue regeneration. Improvement develops over 4–12 weeks. Best used as a complement to other therapies or for men seeking non-pharmaceutical enhancement (Epifanova et al., 2020).

Low-Intensity Shockwave Therapy (LiSWT): Acoustic wave therapy stimulates neovascularization and endothelial progenitor cell recruitment. A meta-analysis by Lu et al. (2017, European Urology) demonstrated significant improvement in IIEF scores versus sham treatment.

Penile Botox: Botulinum toxin injection into the corpus cavernosum relaxes smooth muscle, potentially improving basal blood flow. Early clinical data is encouraging but the treatment remains investigational.

Combination Approaches

Mounting evidence supports combining therapies across treatment tiers:

• Low-dose daily tadalafil + P-Shot: Maintains NO pathway activity while regenerating vascular tissue
• Testosterone optimization + PDE5 inhibitor: Converts approximately 60% of hypogonadal non-responders (Shabsigh et al., 2004)
• LiSWT + PRP: Synergistic neovascularization (Scott et al., 2019)
• Injectable therapy + lifestyle modification: Maximizes long-term outcomes while providing immediate functional results

Penile Implant Surgery: The Definitive Solution

For men with severe, treatment-resistant ED who have failed or are not candidates for other therapies, penile implant surgery is the gold standard.

Modern three-piece inflatable devices (Coloplast Titan, Boston Scientific AMS 700) provide:

• On-demand rigidity with natural flaccidity between uses
• Patient satisfaction rates exceeding 90% (Bernal & Henry, 2012)
• Partner satisfaction rates of 85–90%
• Device longevity of 15–20 years before revision
• Infection rates <1% with antibiotic-coated devices

> "I tell every man: we will find something that works for you. Whether it's optimizing your Viagra, starting Trimix, combining regenerative therapies, or discussing an implant — there is a path to satisfactory sexual function. Giving up is never the right answer." > — Dr. Lloyd Tapper, PhD, NP

The ReGenesis Advantage: Every Option Under One Roof

Most clinics offer one or two treatment options. If the treatment they offer doesn't work, you're referred elsewhere — often with months of additional waiting.

At ReGenesis, our Edmonton and Calgary clinics offer the complete treatment spectrum: lifestyle optimization, all three PDE5 inhibitors, injectable therapies (Bimix, Trimix, Quadmix), P-Shot, penile Botox, shockwave therapy, and referral coordination for penile implant surgery.

This means our treatment recommendations are based entirely on what is clinically appropriate for you — not limited by what we have available.

References

1. Carson CC, et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. *Urology*. 2002;60(Suppl 2):12-27.
2. McCullough AR, et al. Achieving treatment optimization with sildenafil citrate in patients with erectile dysfunction. *Urology*. 2002;60(Suppl 2):28-38.
3. Hatzimouratidis K, et al. Guidelines on male sexual dysfunction. *European Urology*. 2010;57(5):804-814.
4. Shabsigh R, et al. Testosterone therapy in hypogonadal men and potential prostate cancer risk. *International Journal of Impotence Research*. 2004;16:S24-S28.
5. Coombs PG, et al. A review of outcomes of an intracavernosal injection therapy programme. *BJU International*. 2012;110(11):1787-1791.
6. Lu Z, et al. Low-intensity extracorporeal shock wave treatment improves erectile function. *European Urology*. 2017;71(2):223-233.

Schedule Your Assessment

Confidential assessments available. Same-week appointments for new patients.

Ready to Take the Next Step?

Book a confidential assessment with a ReGenesis clinician.

Call 587.635.3414